Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI and Currentum in connection with the acquisitions of Gullikssons El, Elkalkyl och Elprojektering and Reglerab
Mandate

Vinge advises Axcel VI and Currentum in connection with the acquisitions of Gullikssons El, Elkalkyl och Elprojektering and Reglerab

September 13, 2022 Employment and Benefits M&A Banking and Finance Real Estate and Construction

Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of J. Gullikssons El Aktiebolag, Elkalkyl och Elprojektering i Sverige AB and Reglerab AB.

The companies provide services in planning, installation and service in the electrical and construction sectors and are based in Stockholm and Mälardalen. Together, the companies have a turnover of approximately SEK 155 million and approximately 100 employees. Following the acquisitions, Currentum is expected to have a turnover of approximately SEK 3 billion and will engage just over 1,000 employees.

Vinge’s team consisted of partner Christina Kokko together with Carl Fredrik Wachtmeister, Linnea Petersson and Philip Moré (M&A), Isak Willborg (Construction), Sara Strandberg (Employment), Calle Tengwall Pagels (Financing), Frida Ställborn (Real Estate) and Anna Ekdahl Roos (project assistant).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026